UC Riverside's department of biology receives $953,000 GAANN grant
RIVERSIDE, Calif.-- May 13, 2003 -- UC Riverside biologists Rich Cardullo and Kim Hammond have received a $953,000 'Graduate Assistance in Areas of National Need' (GAANN) grant from the Department of Education for three years beginning this fall. This is the second time the department of biology at UC Riverside has received the grant. While Cardullo and Hammond are the PI (principle investigato...Science highlights of AAN Annual Meeting in Honolulu March 29 April 5
ST. PAUL, MN (April 14, 2003) Progress in the understanding of multiple sclerosis, the treatment of epilepsy, the progression of Alzheimers disease, the prevention of stroke, and even the neuroscience of golf were among the highlights of more than 1,300 scientific studies presented at the 55th Annual Meeting of the American Academy of Neurology, held in Honolulu, Hawaii, March 29 April 5, 2003....Biological and chemical agents in terrorism examined at AAN Annual Meeting
HONOLULU, HI (March 31, 2003) - The neurological effects of bioterrorism and the history of biological warfare will be examined at the American Academy of Neurology 55th Annual Meeting taking place this week in Honolulu.... ...On Tuesday, April 1, "Biological Toxins in War and Terrorism - An Historical Overview" will be presented by Shrikant Mishra, MD, Department of Neurology, Keck School of Med.... . . HORSHAM, PA (July 5, 2000) -- Scientists at Cell Pathways, Inc. (Nasdaq: CLPA) and their collaborators have identified a new drug target that may play a key role in cancer cell survival. Exisulind (Aptosyn™) and other compounds in the company's family of selective apoptotic antineoplastic drugs (SAANDs) inhibit this target, cyclic GMP phosphodiesterases of the PDE5 and PDE2 gene f.... HORSHAM, PA (April 3, 2000) -- CP461, a second generation selective apoptotic antineoplastic drug (SAAND) compound, under development by Cell Pathways, Inc. (Nasdaq: CLPA), significantly enhanced the anti-tumor activity of Taxol™ (paclitaxel) in a classic mouse model of human breast cancer, according to a presentation by company scientists this week at the annual meeting of the American A.... HORSHAM, PA (April 3, 2000) -- Scientists from Cell Pathways, Inc. (Nasdaq: CLPA) and their collaborators are presenting new laboratory findings on the novel mechanism of action and anti-cancer activity of the company's selective apoptotic anti-neoplastic drugs (SAANDs) at the annual meeting of the American Association for Cancer Research (AACR) this week in San Francisco. The company's lead...Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
. HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the...